The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with variable clinical outcome, accounting for at least 25-30 % of adult non-Hodgkin lymphomas. Approximately one third of DLBCL patients are not cured by the currently used treatment regimen, R-CHOP. Hence, new treatment str...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biomark Res
Main Authors: Reinholdt, Linn, Laursen, Maria Bach, Schmitz, Alexander, Bødker, Julie Støve, Jakobsen, Lasse Hjort, Bøgsted, Martin, Johnsen, Hans Erik, Dybkær, Karen
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4908729/
https://ncbi.nlm.nih.gov/pubmed/27307990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-016-0067-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados